Reva Medical ’s management is in Australia this week, spruiking the good news from the company’s recent trials.

The US-based, ASX-listed company has told investors it is confident of taking the world’s second absorbable stent to market, provided an upcoming clinical trial is successful. Reva is about to test its stent on another 125 patients, after successfully completing a clinical trial on 26.